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AntioxidantThe medical use of nitroglycerin (GTN) is limited by patient tolerance. The present study evaluated the role of
mitochondrial Complex I in GTN biotransformation and the therapeutic effect of mitochondrial antioxidants.
The development of GTN tolerance (in rat and human vessels) produced a decrease in mitochondrial O2 con-
sumption. Co-incubation with the mitochondria-targeted antioxidant mitoquinone (MQ, 10−6 mol/L) or
with glutathione ester (GEE, 10−4 mol/L) blocked GTN tolerance and the effects of GTN on mitochondrial res-
piration and aldehyde dehydrogenase 2 (ALDH-2) activity. Biotransformation of GTN depended on the mito-
chondria being functionally active, particularly mitochondrial Complex I. Tolerance induced mitochondrial
ROS production and oxidative stress, though these effects were not detected in HUVECρ0 cells or Complex I
mutant cells. Experiments performed to evaluate Complex I-dependent respiration demonstrated that its in-
hibition by GTN was prevented by the antioxidants in control samples. These results point to a key role for
mitochondrial Complex I in the adequate functioning of ALDH-2. In addition, we have identiﬁed mitochondri-
al Complex I as one of the targets at which the initial oxidative stress responsible for GTN tolerance takes
place. Our data also suggest a role for mitochondrial-antioxidants as therapeutic tools in the control of the
tolerance that accompanies chronic nitrate use.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Nitroglycerin (glyceryl trinitrate, GTN) has long been the principal
therapeutic agent for the treatment of acute angina and congestive
heart disease [1]. Its action is generally attributed to its bioconversion
into the relaxant agent nitric oxide (NO), which acts on the enzyme
soluble guanylate cyclase (sGC) [1–3]. However, most studies sup-
porting the existence of such a pathway have demonstrated increases
of NO only when GTN concentrations considerably exceeded the plas-
ma levels reached during clinical dosing [4]. Several enzymes have
been proposed as catalysts of the bioactivation of GTN [5], but some
evidence suggests that aldehyde dehydrogenase-2 (ALDH-2) is essen-
tial for GTN-triggered vasodilation in rodents and humans [6,7], and
that this reaction is accelerated by an allosteric action of NAD+.r Peset Foundation, Avda Gas-
2757; fax: +34 961622409.
l rights reserved.The medical use of GTN is limited by tolerance, which develops
following prolonged administration or high dosage. This phenomenon
has been related to various mechanisms, in particular desensitization
of sGC [8] and impairment of GTN biotransformation by inhibition of
ALDH-2 [6,7,9]. These actions, like others associated with GTN, have
been linked to an increase in the production of reactive oxygen spe-
cies (ROS) [10], which seems to depend on the decreased function
of the mitochondrial electron transport chain (ETC) [11].
Although antioxidants have been shown to be effective in dimin-
ishing oxidative stress during the inﬂammatory process, there is a
lack of conclusive evidence regarding the clinical relevance of these
beneﬁcial effects in many pathological settings. This may be due to
the limited capacity of these molecules to reach and/or accumulate
within mitochondria. The most abundant cellular antioxidant is gluta-
thione (GSH), which has been attributed multiple redox-related
functions in the cell. As the cellular up-take of this molecule is rather
inefﬁcient, several strategies have been developed to increase its
intracellular levels, one of which is glutathione ester (GEE), a mole-
cule that is converted intracellularly into GSH with a 1:1 molar
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out difﬁculty. Selective mitochondria-targeted compounds constitute
another group of intracellular low molecular weight molecules with
antioxidant properties. One example is mitoquinone Q (MQ), which
consists of the lipophilic TPP (triphenylphosphonium) cation cova-
lently linked to ubiquinone [12]. Due to this conjugation with TPP,
MQ is readily transported into the cell and can concentrate several
hundred-fold within mitochondria attracted by the large mitochon-
drial inner membrane potential [13]. The active antioxidant form of
MQ is the reduced form of ubiquinol, which is regenerated by the
ETC and selectively blocks mitochondrial oxidative damage by detox-
ifying ROS [14]. This and other mitochondria-targeted antioxidants
have been shown to protect mitochondria from oxidative stress in
different models [15–17].
The present study conﬁrms and expands the theory that toler-
ance to GTN is related to the oxidative stress that causes inhibition
of ALDH-2. Furthermore, using antioxidants such as GEE and the
mitochondria-targeted antioxidant MQ, inhibitors of Complex I of
the ETC such as rotenone, and a cellular model of Complex I mutant
ﬁbroblasts, we show that mitochondrial Complex I plays a key role
in the aforementioned effect of ALDH-2. In fact, the NADH generated
during the ALDH-2-catalyzed reaction is reoxidized back to NAD+ by
Complex I (NADH-ubiquinone oxidoreductase) of the respiratory
chain. Thus, the ability to metabolize GTN and accelerate this reaction
may depend on the capacity of mitochondrial Complex I to reoxidize
the NADH that is converted into NAD+. Moreover, we have identiﬁed
mitochondrial Complex I as one of the targets at which the initial
oxidative stress responsible for GTN tolerance takes place.2. Materials and methods
2.1. Experimental models
Human umbilical cords were obtained from the Department of Gy-
naecology (University Hospital Doctor Peset, Valencia, Spain) and cut
into rings. Upon anesthesia with sodium pentobarbital (65 mg·kg−1,
i.p.), male Sprague–Dawley rats (200–250 g; Harlan, Barcelona) were
sacriﬁced and their thoracic aorta cut into 5 mm rings. Rings from tho-
racic aorta and human umbilical arteries or veinswere suspended in an
organ bath containing Krebs solution (37 °C), ([in ×10−3 mol/L] NaCl
118, KCl 4.75, CaCl2 1.9, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25 and glucose
10.1) as described previously [11].
Human umbilical vein endothelial cells (HUVEC) and human
umbilical artery endothelial cells (HUAEC) were obtained from fresh
umbilical cords and cultured in medium 199 (Cambrex, Walkersville,
MD) as previously described [18]. In accordance with the Declara-
tion of Helsinki, all donors of umbilical cords were informed of the
purpose, risks, procedures and possible beneﬁts of the study and
gave their express consent. The study was approved by the local
ethics committee.
The murinemacrophage cell line RAW 264.7 was obtained from the
American Type Culture Collection (Manassas, VA) and was employed
in this study as an additional cell type due to its capacity for induction
of GTN tolerance, as already described [6]. RAW 264.7 cell cultures
were maintained at sub-conﬂuence at 37 °C in a 5% CO2 humidiﬁed at-
mosphere using RPMI medium supplemented with 10% fetal bovine
serum (FBS), 100 IU/mL penicillin and 10 μg/mL streptomycin.
For the generation of HUVECρ0, 50 ng/mL ethidium bromide was
added to the medium for 7 days to inhibit mitochondrial gene
transcription and, consequently, mitochondrial activity [9]. Pyruvate
(110 mg/mL) and uridine (50 μg/mL) were used as alternative
sources of energy and nucleotide. Lack of mitochondrial gene ex-
pression was conﬁrmed by Western blot analysis for cytochrome
c oxidase subunit II and the absence of respiratory function was eval-
uated by measuring mitochondrial oxygen (O2) consumption.Complex I mutant cells (Y204C/C206G) were kindly donated by
Dr. A Rotig (INSERM, Paris, France). This human ﬁbroblast cell line
carries a mutation in the subunit Ndufv1 of the mitochondrial Com-
plex I that causes a considerable reduction in mitochondrial Complex
I activity (a residual activity of 18%).
2.2. Vascular contractility studies
Rings were suspended in an organ bath containing Krebs solution
(37 °C), as described previously [11]. GTN-tolerance was induced
in vitro by incubating rings for 3 h with GTN (5×10−6 mol/L) follow-
ing the protocol reported in a previous study [11], and the Complex I
inhibitor rotenone (10−9 mol/L) was added for 3 h to assess the role
of Complex I in GTN tolerance. Relaxation–response curves were
obtained by adding cumulative concentrations of GTN (10−10 to
10−4 mol/L) or the commonly used NO donor, DETA-NO ((Z)-1-[N-
(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-dio-
late; 10−8 to 10−4 mol/L). Some experiments were performed in
aortic denudated rings and, when necessary, MQ (10−6 mol/L) was
added 1 h prior to incubation with GTN or rotenone and maintained
thereafter. In preliminary experiments the lipophilic cation linkers
TPP (5×10−6 mol/L) or TPMP (5×10−6 mol/L), the former of
which is responsible for targeting MQ to mitochondria, produced no
effect on vascular responses. The adequate concentration (− log
[M]) for producing 50% relaxation (pEC50) was established using a
non-linear regression analysis with Graph Pad Software.
2.3. ALDH-2 activity
ALDH-2 activity was determined in homogenates of aortic rings
and mitochondrial extracts from HUVEC, Raw 264.7 or Complex I
mutant cells (treated as described above) by monitoring NADH for-
mation from NAD+ using a Uvikon 941 dual-beam spectrophotome-
ter at room temperature at 340 nm. Isolation of mitochondria was
performed using “Mitochondria isolation kit” (BioChain Institute,
Inc.) according to the manufacturer's instructions. Deep-frozen aortic
rings were homogenized for 30 s in a liquid nitrogen precooled dis-
membranator (B. Braun Biotech International GmbH, Melsungen,
Germany). The powdered tissue was dispersed in 5 vol ice-cold aque-
ous 30 mM potassium phosphate buffer (deoxygenated with nitrogen
gas), pH 7.5, vortexed, sonicated, and centrifuged at 10,000 g for
10 min.
The assay mixture (0.5 mL) contained 100 mM Tris–HCl (pH 8.5),
1 mM NAD+, 1 mM 4-methylpyrazole, and 100 μg protein. The reac-
tion was started by addition of 1 mM propionaldehyde to the cuvette,
and absorbance changes were recorded for 10 min. The mean rate of
absorbance change was taken as a measure of ALDH-2 activity
(0.0125 A340 was equivalent to 1 nmol/mg/min). The ALDH-2 inhibi-
tor benomyl (10−5 mol/L) was used as a negative control. The pres-
ence of ALDH-2 in the homogenates was also evaluated by Western
blot.
2.4. Protein extracts and immunoblotting
Whole-cell protein extracts were obtained from t-25 ﬂask cell cul-
tures by lysing cell pellets in 50–100 μL complete lysis buffer
(2×10−2 mol/L HEPES pH=7.4, 4×10−1 mol/L NaCl, 20% (v/v) glyc-
erol, 1×10−4 mol/L EDTA, 1×10−5 mol/L Na2MoO4, 1×10−3 mol/L
DTT) supplemented with protease inhibitors (“Pefabloc” and “Com-
plete Mini” protease inhibitor cocktail, both from Roche Diag-
nostics) and phosphatase inhibitor (10−2 mol/L NaVO3, 10−5 mol/L
NaF, 10−2 mol/L p-nitrophenylphosphate and 10−2 mol/L β-
glycerolphosphate). Samples were vortexed, incubated in ice for
15 min, vortexed once again and centrifuged at 16,100 g for 15 min
at 4 °C. Protein content was quantiﬁed with the “BCA Protein Assay
Kit” (Pierce, Thermo Scientiﬁc, Rockford, IL). SDS-PAGE and WB
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CA), using 50 μg of the protein extract. The following primary anti-
bodies were employed: polyclonal anti-ALDH-2 (1:4000), kindly
donated by Dr. Stamler (Duke University, North Carolina, USA);
anti-actin at 1:500 (Sigma-Aldrich, Steinheim, Germany); the mono-
clonal anti-Complex IV subunit II, at 1:1000 (Molecular Probes, Invi-
trogen, Eugene, OR); and anti-tubulin at 1:5000 (Sigma-Aldrich,
Steinheim, Germany). Secondary peroxidase-labeled antibodies in-
cluded anti-mouse antibody (Dako, Glostrup, Denmark) at 1:2000
and anti-rabbit IgG (Vector laboratories, Burlingame, CA) at 1:5000.
Immunolabeling was detected using the enhanced chemiluminescent
reagent ECL (Amersham, GE Healthcare, Little Chalfont, UK) or Super-
Signal WestFemto (Pierce, Thermo Scientiﬁc, Rockford, IL). The signal
was visualized with a digital luminescent image analyzer (FUJIFILM
LAS 3000, Fujiﬁlm), and densitometric analysis was performed using
ImageQuant software v. 4.0.
2.5. Measurement of O2 consumption, NO production, ATP and
cGMP levels
Rat aortas (98±1.05 mg wet weight) and human umbilical arter-
ies or veins (195±2.6 or 198±3.2 mg wet weight, respectively)
were cut into rings and suspended in Krebs solution. HUVEC,
HUVECρ0, HUAEC, Raw 264.7 cells and Complex I mutant cells were
resuspended (5×106cells/mL) in Krebs supplemented with L-argi-
nine (3×10−4 mol/L) and HEPES (25×10−3 mol/L). Induction of
GTN tolerance, treatment with rotenone and use of antioxidants
were the same as in the vascular reactivity studies. When adminis-
tered acutely, the concentration of GTN employed (5×10−6 mol/L)
had no effect on mitochondrial O2 consumption, despite producing
maximal relaxation of vascular rings (data not shown). The afore-
mentioned tissues were then placed in a gas-tight chamber and O2
consumption was measured with a Clark-type O2 electrode (Rank
Brothers, Bottisham, UK) [19]. Sodium cyanide (10−3 mol/L) was
employed to conﬁrm that O2 consumption was mainly mitochondrial
(95% to 99%). Measurements were collected using the data-
acquisition device Duo.18 (WPI, Stevenage, UK). A hyperbolic func-
tion was employed to describe the relationship between O2 concen-
tration and the rate of O2 consumption (VO2). The maximal rate of
O2 consumption (VO2max) was calculated according to its analogy
with the Michaelis–Menten constant. A Trypan blue exclusion test
revealed no alterations of cell viability.
NO concentration in the cell medium was monitored throughout
the 3 h incubation period with GTN with the aid of an NO electrode
(ISO-NOP; WPI, Stevenage, UK), as described previously [20]. The
NO donor DETA-NO (10−5 mol/L) was added at the end of each ex-
periment as an internal control. Changes in intracellular NO were
also evaluated by incubating cells with the ﬂuorescent probe diami-
nodiﬂuoroﬂuorescein diacetate (DAF-FM DA, 10−6 mol/L). For these
experiments, the medium was changed to HBSS supplemented with
glucose (20×10−3 mol/L), L-arginine (3×10−4 mol/L) and DAF-FM,
incubated for 30 min, and measured using a Fluoroskan plate reader
(TL, Franklin, MA). ATP concentration (nmol/mg protein) was deter-
mined by ﬂuorimetry and was compared with a standard curve for
ATP using an ATP Bioluminescence Assay Kit HSII (Roche, Mannheim,
Germany) and a Fluoroskan microplate reader (Thermo Labsystems,
OH). cGMP levels were measured using the Biomol assay kit (Plymoth
Meeting, PA) [11].
2.6. Measurement of ROS production, GSH content and Complex I activity
Different methods were employed to evaluate ROS. Total ROS pro-
duction was assessed by ﬂuorimetry following incubation (30 min)
with the ﬂuorescent probe (5×10−6 mol/L) 2′,7′-dichlorodihydro-
ﬂuorescein diacetate (DCFH-DA), as described elsewhere [21]. Quan-
titative assessment of hydrogen peroxide (H2O2) was performed withthe Amplex RedR H2O2/peroxidase assay kit (Molecular Probes,
Eugene, OR) [22].
GSH content was measured by confocal microscopy (Leica, Heidel-
berg, Germany) following incubation (30 min) with the ﬂuorescent
probe 5-chloromethylﬂuorescein diacetate (CMFDA, 10−6 mol/L).
A more accurate determination of GSH and GSSG was performed
using an HPLC method. For GSSG determination, samples (0.5 mL)
were treated at 4 °C with 0.5 mL ice-cold perchloric acid (6%) con-
taining 40×10−3 mol/L NEM (N-ethylmaleimide; Sigma Chem. Co.,
St. Louis, MO) in order to prevent GSH oxidation, and 2 mM BPDS
(bathophenanthroline disulfonic acid, Sigma Chem. Co., St. Louis,
MO), as described by Asensi et al. [23]. To measure total glutathione,
0.5 mL was incubated at 4 °C with 0.5 mL trichloroacetic acid (30%).
Samples were then centrifuged at 15,000 g for 5 min at 4 °C and the
acidic supernatants were employed for measurement of GSH, GSSG
and total glutathione.
GSSG was measured by HPLC as previously described [23]; 0.5 mL
of the acidic supernatants (see above) were derivatized by adding
50 μL of 1 mM γ-glutamyl-glutamate (Sigma Chem. Co., St. Louis,
MO) prepared in 0.3% perchloric acid. Subsequently, pH was ad-
justed to 8.0 with KOH (2 mol/L)/morpholinopropane sulfonic acid
(0.3 mol/L), samples were centrifuged, and an aliquot of 25 μL of the
supernatant was mixed with 50 μL of 1% 1-ﬂuoro-2,4-dinitrobenzene
(Sigma Chem. Co., St. Louis, MO). Derivatization was completed in
45 min and desiccated samples were maintained stable at −20 °C
for several weeks until injection.
The activity of mitochondrial Complex I was assessed by calculat-
ing the NADH oxidation rate [24], measured with the Multiscan Plate
Reader Spectrophotometer as the decrease in absorbance at 340 nm.
In short, a cellular homogenate (20 μL, 0.3 mg) was added to 1 mL
of potassium phosphate buffer (10−2 mol/L) containing NADH
(10−4 mol/L) at 37 °C. Basal absorbance was recorded for 1 min,
after which 5 μL of decylubiquinone (10−2 mol/L) were added. The
rate of NADH oxidation (interpreted as Complex I activity) was mea-
sured over 2 min and conﬁrmed by inhibition with rotenone
(6×10−6 mol/L). The NADH oxidation rate was calculated from
the time-dependent decrease of the slope of absorbance using a com-
bined NADH-ubiquinone extinction coefﬁcient of 6.81×10−3 mol/
L cm−1 at 340 nm. Complex I-dependent respiration was evaluated
in digitonin-permeabilized cells using a Clark-type O2 electrode
(Rank Brothers, Bottisham, UK) [21]. To do this, O2 consumption
was monitored in the presence of the Complex I substrates malate
(0.4×10−3 mol/L) and glutamate (3×10−2 mol/L), the Complex II
substrate succinate (10−2 mol/L), or the Complex I inhibitor rote-
none (6×10−6 mol/L) [25].
2.7. Drugs and solutions
Phenylephrine (Phe), sodium cyanide, KCl, NADH, ubiquinone,
succinate, rotenone, glutamate, malate, digitonine, arginine, HEPES,
uridine, NEM, TPP, TPMP, glucose, DTNB, trypan blue, NADH, glutathi-
one reductase, γ-glutamyl-glutamate, BPDS, methypyrazole, H2O2
and hemoglobin were obtained from Sigma-Aldrich (St. Louis, MO).
Propionaldehyde was supplied by Fluka (Milano, Italy). The GTN
employed in this study is a clinically-used preparation (Solinitrina®,
Allmirall, Barcelona, Spain). GTN patches were obtained from
Schering-Plough (Madrid, Spain). Na-pyruvate was supplied by
Gibco (BRL, Gaithesburg, MD). Ethidium bromide was purchased
from SERVA (Heidelberg, Germany), and HBSS and M199 were pro-
vided by Cambrex (Verviers, Belgium). DETA-NO was obtained from
Alexis (San Diego, CA), and DAF-FM, DHR and DCFH-DA were pur-
chased from Calbiochem (San Diego, CA). CMFDA was obtained
from Molecular Probes (Eugene, OR). MQ was synthesized according
to the published method [26]. The concentration of 10−6 mol/L of
MQ used in the present study was selected from concentration–effect
experiments (0.001–2 μM) to assess the capacity for scavenging ROS
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Fig. 1. Dose-dependent relaxation curves for the effects of GTN (10−10 to 10−4 mol/L)
on precontracted (Phe 10−6 mol/L) vascular rings of rat aorta (A) and human umbilical
artery (B) and vein (C), in which GTN tolerance was induced in vitro. The effect of
cotreatment with the mitochondria-targeted antioxidant MitoQ (MQ 10−6 mol/L) or
the Complex I inhibitor rotenone (10−9 mol/L) is shown. Each point represents the
mean±SEM of 5–7 separate experiments.
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addition, we have previously found this concentration to have bene-
ﬁcial effects in different models of oxidative stress [11,27].
MQ was used alone in all of the parameters studied in the present
work and did not induce signiﬁcant changes, which rules out the
possibility of secondary effects. The characterization of this molecule
is described in Supplementary Fig. 2.
2.8. Data analysis
Unless stated otherwise, all values are expressed as the mean
±S.E.M. of at least 5 experiments. Statistical analysis was performed
with one-way ANOVA with post-hoc corrections, followed by the Stu-
dent's t test for unpaired samples (Graph Pad Software). Signiﬁcance
was deﬁned as Pb0.05.
3. Results
3.1. Tolerance to GTN vasorelaxation
GTN treatment induced vascular tolerance in several endothelium
models. Fig. 1 shows dose-dependent relaxation curves by GTN
(10−10 to 10−4 mol/L) in precontracted (Phe 10−6 mol/L) rings of
rat aorta and human umbilical artery and vein. (Fig. 1A, B and C re-
spectively). The vessels were pre-treated with GTN (5×10−6 mol/L)
or rotenone (10−9 mol/L), alone or in the presence of MitoQ
(10−6 mol/L). The pEC50 values are summarized in Table 1. Continu-
ous treatment with GTN caused a signiﬁcant rightward shift in the
GTN concentration–response curves, indicating the development of
GTN-induced vascular tolerance. In GTN-tolerant vessels, the maxi-
mal GTN relaxation values were signiﬁcantly diminished. Administra-
tion of rotenone, an irreversible inhibitor of Complex I, caused a
signiﬁcant rightward shift in the GTN-induced relaxation of the stud-
ied vessels similar to that observed in the presence of GTN. When ro-
tenone was added in the presence of GTN, the result was similar to
that obtained with rotenone alone.
Treatment with MQ during the induction of tolerance restored the
acute vasorelaxant effect of GTN, but not that of rotenone, suggesting
that inhibition of Complex I is as relevant as that of mitochondrial
ROS in the development of GTN-tolerance. Similar results were
obtained in all the vessels studied and in the presence of another
mitochondrial antioxidant, GEE (Table 1).
pEC50 values with DETA-NO (10−8 to 10−4 mol/L) were similar
in controls (6.03±0.09), in GTN-tolerant (5.97±0.04) and
rotenone-treated (5.96±0.02) aortas. Incubation with DETA-NO
(5×10−6 mol/L, 3 h) did not induce tolerance to the effects of GTN
(7.87±0.07) when administered later (data not shown). These re-
sults argue against desensitization of sGC as a possible mechanism
of GTN tolerance.
3.2. GTN biotransformation
The activity and expression of ALDH-2, the enzyme responsible for
GTN biotransformation, is represented in Fig. 2. ALDH-2 activity
(Fig. 2A) was signiﬁcantly (Pb0.001) diminished in GTN-tolerant aor-
tas and in cellular models of HUVEC and Raw 264.7 cells treated with
GTN with respect to that in controls. In a similar manner, ALDH-2
activity was inhibited in the presence of rotenone or in Complex I
mutant cells (Pb0.001), which conﬁrms that functional Complex I is
essential for GTN biotransformation. This inhibition was blocked by
the presence of MQ during the induction of GTN tolerance in all
three control experimental models; however, MQ did not restore
the inhibition induced by rotenone. The presence of the antioxi-
dant GEE produced similar effects to those observed with MQ (data
not shown).The presence of ALDH-2 was conﬁrmed by Western blot (Fig. 2B)
using whole-cell protein extracts of all the cellular models assayed
(Raw 264.7, HUVEC and Complex I mutant cells). Densitometry
revealed no signiﬁcant differences between any of the treatments
(Fig. 2B).3.3. Mitochondrial O2 consumption
As shown in Fig. 3 (A, representative traces and B, data quantiﬁ-
cation) and Table 2, the rate of O2 consumption decreased in vessels
and cells in which GTN-tolerance was induced (rat aorta, human
umbilical artery and vein, HUVEC and Raw 264.7 cells). A rotenone
dose–response curve demonstrated that 10−9 mol/L rotenone
Table 1
pEC50 of the dose-dependent relaxation curves by GTN in rat aorta and human umbil-
ical cord artery and vein rings.
Rat aorta HUA HUV
Control 8.31±0.10 8.25±0.08 8.03±0.06
MQ 8.04±0.07 8.12±0.09 8.05±0.08
Rot 6.41±0.05⁎ 6.38±0.05⁎ 6.43±0.06⁎
Rot+MQ 6.56±0.06⁎ 6.41±0.04⁎ 6.47±0.04⁎
Rot+GTN 6.38±0.06⁎ 6.36±0.04⁎ 6.41±0.05⁎
GTN 7.03±0.07⁎ 6.85±0.06⁎ 6.87±0.06⁎
GTN+MQ 7.83±0.06† 7.84±0.06† 7.85±0.05†
GTN+GEE 7.80±0.04† 7.88±0.08† 7.89±0.07†
Rat aortic rings, human umbilical artery (HUA) and human umbilical cord vein
(HVA) rings were precontracted with Phe (10−6 mol/L). GTN tolerance was induced
in vitro and relaxation was determined upon the addition of GTN (concentration
range of 10−10 to 10−4 mol/L) in all samples. Vascular rings were preincubated with
MQ (10−6 mol/L), GEE (10−4 mol/L), rotenone (10−9 mol/L), GTN (5×10−6 mol/L)
or a combination of Rot+MQ, Rot+GTN, GTM+MQ, GTN+GEE or underwent
no pretreatment (control). Data are represented as the mean±SEM of 5–7 indepen-
dent experiments.
⁎ Pb0.001 vs control.
† Pb0.001 vs GTN.
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obtained with GTN (10−6 mol/L) (Supplementary Fig. 3). Treatment
with MQ during the induction of tolerance prevented these inhibitory
effects of GTN in all the control samples, but not in Complex I mutant
cells or HUVECρ0, or after treatment with rotenone. GEE reproduced
the result obtained with MQ (data not shown). As expected, the in-
hibition of mitochondrial O2 consumption during GTN tolerance and
after administration of rotenone produced a decrease in ATP levels
in HUVEC cells (around 50% in both cases, data not shown).0
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Fig. 2. Effects of pre-incubation with GTN (5×10−6 mol/L, 3 h), GTN+MQ (10−6 mol/L), ro
plex I mutant and Raw264.7 cells (A) and ALDH-2 protein expression studied by Western b
mean±SEM of 5–7 experiments.*Pb0.001 vs. control.Treatment with MQ during the induction of tolerance prevented the
inhibitory effect of GTN on ATP generation but did not produce any
changes after treatment with rotenone (data not shown).
In accordance with previous results [11], the addition of GTN
(5×10−6 mol/L) in HUVEC did not induce any NO signal, whereas a
robust increase was noted when DETA-NO (10−5 mol/L) was mea-
sured with an NO electrode and by ﬂuorescence microscopy (data
not shown).
3.4. Role of mitochondria in GTN-induced cGMP production
HUVECρ0 cells were employed to conﬁrm the role of functional
mitochondria and, particularly, the role of Complex I in GTN bioactiv-
ity and ALDH-2 activity. The rhoº phenotype was veriﬁed when the
absence of the Cytochrome c oxidase subunit II was conﬁrmed by
WB. (Fig. 4B). Additionally, we employed cells treated with rotenone
or human Complex I mutant cells (Y204C/C206G), which display only
18% Complex I activity. The acute addition of GTN increased cGMP
levels in HUVEC but not in HUVECρ0 or in Complex I mutant cells,
or when cells were pre-incubated with GTN, or after treatment with
rotenone (Fig. 4A). Co-incubation with MQ blocked the effect induced
by incubation with GTN in controls but not in Complex I mutant cells
or in HUVECρ0. GEE had a similar effect (data not shown). HUVEC,
HUVECρ0 and Complex I mutant cells exhibited an increased cGMP
production following addition of DETA-NO (10−4 mol/L), which
rules out the possibility that sGC was affected. Preincubation of
HUVEC with DETA-NO (5×10−6 mol/L, 3 h) did not modify the in-
crease in cGMP that followed the acute addition of GTN (data not
shown). These data highlight the key role of mitochondrial Complex
I in the biotransformation of GTN.0
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Pre-incubation of HUVEC with GTN signiﬁcantly increased ROS
generation. This was detected with the ROS-sensitive ﬂuorescentprobe DCFH-DA and the aid of confocal microscopy (Fig. 5A) and ﬂuo-
rimetry (Fig. 5B). A similar ROS increase resulting from GTN pre-
incubation was also observed when H2O2 concentration was evaluated
(Fig. 5C). Co-incubation with MQ reversed the effect of GTN. Similar
Table 2
Modulation of the VO2max in rat aortic rings, human umbilical cord artery rings, human
umbilical cord vein rings, HUVEC and Raw264.7.
Rat aorta HUA HUV HUVECs Raw264.7
Control 32.1±1 33.3±2 32.8±3 31.4±2 36.5±2
Control+MQ 31.9±1 32.6±2 31.6±2 30.5±2 35.6±2
Rot 17.6±2⁎ 20.8±2⁎ 19.3±2⁎ 20.4±2⁎ 18.5±2⁎
Rot+MQ 18.3±2 22.1±2 20.5±2 20.9±2 20.4±2
GTN 18.4±1⁎ 21.1±2⁎ 20.2±4⁎ 21.1±2⁎ 19.3±1⁎
GTN+MQ 33.2±2† 32.8±3† 31.5±3† 30.3±2† 35.6±1†
Vascular rings or cell cultures underwent no preincubation (control), were pre-
incubated with GTN (5×10−6 mol/L, 3 h), or with rotenone (1×10−9 mol/L) in all
three cases in the absence or in the presence of MQ (10−6 mol/L). Data are shown as
mean±SEM of 5–7 independent experiments.
⁎ Pb0.001 vs controls.
† Pb0.001 vs GTN.
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of HUVECρ0 cells with GTN nor acute administration of GTN to
HUVEC, HUVECρ0 or Complex I mutant cells produced any increase in
ROS-related ﬂuorescence.
Oxidative stress is related to both an increase in ROS produc-
tion and a decrease in antioxidant content. Using different detection
methods, we found that the level of the major cellular antioxidant
GSH in HUVEC was signiﬁcantly lower (Pb0.05) after pre-
incubation with GTN, as shown in Fig. 5D and E. No changes in GSH
concentration were observed in HUVECρ0 or Complex I mutant cells
following treatment with GTN or in rotenone-treated HUVEC. Treat-
ment with MQ reversed the effect of GTN. In addition, we also evalu-
ated the GSH:GSSG ratio, which is often employed as a reliable
indicator of redox stress. Fig. 5F reveals that incubation of HUVEC
with GTN led to a decrease in the GSH:GSSG ratio, a pattern that
was not reproduced in rotenone-treated cells in HUVECρ0 or Complex
I mutant cells treated with GTN. Again, co-incubation with MQ re-
versed the effects of GTN. As suggested by these data, rotenone at
the concentration of 10−9 M does not affect the redox status of
HUVEC cells.3.6. Complex I activity
The speciﬁc effect of GTN on Complex I activity was also evaluated.
As represented in Fig. 6A, pre-incubation with GTN exerts an inhibito-
ry effect on mitochondrial Complex I activity in HUVEC, calculatedcGMP
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blocked the effect of GTN tolerance on cGMP levels in HUVEC but not in HUVECρ0 or in Co
the cell types. *Pb0.001 vs. control. †Pb0.001 vs HUVEC cells. (B) Western blot analysis of
control charge.from the rate of NADH oxidation. As expected, a major drop in
Complex I activity was observed in the presence of rotenone and in
Complex I mutant cells which were used as controls. Of note, co-
incubation with either MQ or GEE reversed the inhibitory effect of
GTN. The Complex I-speciﬁcity of the action of GTN was further
characterized through an alternative method involving cells permea-
bilized with digitonin and measurement of Complex I-dependent
respiration. As was to be expected, respiration of permeabilized
HUVEC after administration of the Complex I substrates malate
(0.4×10−3 mol/L) and glutamate (30×10−3 mol/L) was inhibited
by almost 91% with the Complex I inhibitor rotenone (6×10−6 mol/L),
as shown in Fig. 6B. HUVEC incubated with GTN or Complex I
mutant cells respired very poorly with malate and glutamate, while
rotenone-sensitive respiration did not differ to that observed in
the absence of the inhibitor. When succinate (10×10−3 mol/L), a
Complex II electron donor, was added in order to bypass Complex
I-dependent respiration, GTN-treated cells exhibited O2 consumption
rates similar to those of controls. Collectively, these data suggest that
Complex I is the main target of GTN preincubation. Co-treatment
with MQ or GEE (not shown) prevented the action exerted by GTN
preincubation on Complex I-dependent respiration. MQ had no effect
on Complex I mutant cells (data not shown).
4. Discussion
The present study demonstrates that pre-incubation with GTN re-
sults in a reduced vascular relaxation resembling the clinical induc-
tion of GTN tolerance [9,28]. Speciﬁcally, the ﬁndings presented
endorse the fundamental role that mitochondrial dysfunction plays
in the appearance of GTN tolerance. In addition, through the use of
mitochondrial antioxidants such as MQ, and GEE, and by employing
Complex I mutant cells and inhibitors of the electron transport
chain (rotenone), we have shown that mitochondrial Complex I is a
key factor in the regulation of ROS production and ALDH-2 activity
during the biotransformation of GTN.
We postulate that GTN is metabolized depending, in part, on the
ability of mitochondrial Complex I to reoxidize NADH as our data
show that dysfunction of Complex I (presumably through the gener-
ation of NAD+ deﬁcit and/or altered NADH/NAD+ ratio) exerts an in-
hibitory effect on aldehyde dehydrogenase independently of any ROS
participation. This is supported by the fact that ALDH-2 activity is
inhibited by rotenone at a concentration at which this inhibitor com-
promises Complex I without substantial generation of ROS. In addi-
tion, MQ cannot reverse this effect of rotenone ruling out theB
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most likely dual, involving both the described phenomenon and
ROS-induced damage of this enzyme. In this sense, we identify mito-
chondrial Complex I as one of the targets at which the initial
oxidative stress responsible for GTN tolerance takes place. It is thus
likely that prolonged exposure to GTN tolerance manifested as
increased ROS generation accompanied by alterations in NAD+ avail-
ability and/or altered NADH/NAD+ ratio, might provoke conforma-
tional (and other) changes in ALDH-2 undermining its activity.
GTN (5×106 mol/L) was capable of reducing mitochondrial O2
consumption in vascular tissue and endothelial cells in which GTN-
tolerance had been induced in vitro and this inhibition occurred in a
non-competitive manner. Administration in vitro of either MQ or
GEE blocked these effects, except when rotenone was present.
We further explored these processes by employing HUVECρ0 cells,
a mitochondrial antioxidant and mitochondrial Complex I mutantcells, and found mitochondrial Complex I activity to be essential for
proper ALDH-2 function. Collectively, these ﬁndings endorse the fun-
damental role that mitochondrial dysfunction plays in the appearance
of nitrate tolerance, thus underlining the vital role of mitochondrial
Complex I in the biotransformation of GTN.
The dose of GTN (5×10−6 mol/L) used for inducing tolerance did
not cause NO release, thus conﬁrming our previous hypothesis that
biotransformation of these clinically relevant concentrations of GTN
does not cause free NO to be released [19]. The acute addition of
GTN increased cGMP levels and ALDH-2 activity in HUVEC, while
this response was absent following pre-incubation with GTN, thus
suggesting an inhibition of this enzyme's activity. These results are
in accordance with those of a previous report [9] which suggested
that tolerance-inducing concentrations of GTN in vitro lead to inhibi-
tion of both ALDH-2 activity and GTN biotransformation (1,2-GDN
formation). Co-incubation with either MQ or GEE prevented the
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mutant cells and HUVEC treated with rotenone, GTN-stimulated in-
creases in cGMP were absent, which conﬁrmed the metabolization
of GTN by functional mitochondria and, particularly, Complex I. Con-
sidered as a whole, this evidence gives weight to the idea that ALDH-2
contributes to GTN bioconversion and the subsequent increase in
cGMP levels, whereas inhibition of this enzyme is implicated in
GTN-tolerance.
It is widely postulated that prolonged exposure to GTN leads to an
increase in the production of ROS [29–32], which is related to the
development of tolerance and cross-tolerance [9]. The results that
we have obtained with different ﬂuorescence methods conﬁrm this
hypothesis, since incubation with GTN increased the release of ROS
in vascular cells and tissues. Mitochondria seem to be the origin of
this ROS production, as it was absent in HUVECρ0 cells. Furthermore,
treatment with MQ and GEE reversed the increase in ROS and the ox-
idative stress that followed incubation with GTN. The oxidative stress
and Complex I impairment that followed long-term treatment with
GTN could inactivate ALDH-2 or inhibit the ALDH-2 repair system,
both of which effects cause an impairment of GTN bioactivation. In
addition, a potential interaction with superoxide could decrease the
bioavailability of the vasodilator released following GTN bioactiva-
tion. This central role of mitochondrial ROS in nitrate tolerance can
be explained by the structure of ALDH-2. This enzyme has three adja-
cent cysteine thiol-groups in its active site [33]. One of these thiol
groups participates directly in the enzymatic catalysis (aldehyde
breakdown) of ALDH-2. Therefore, oxidation of these thiol groups
leads to inactivation of the enzyme and formation of a disulﬁde or,
at the very least, a sulfenic acid group. The inhibition of ALDH-2 by
oxidative stress provides the missing link between nitrate tolerance
and a diminished organic nitrate bioactivation [34]. During thecatalytic cycle of GTN bioactivation, the drug is de-nitrated, which
leads to the release of 1,2glycerildinitrate and the formation of thioni-
trate (−SNO2) intermediate [35]. Upon nucleophilic attack of a sec-
ond adjacent thiol-group, nitrite is released and a disulﬁde is
formed. Since a detectable amount of the enzyme cannot be reacti-
vated by DTT or dihydrolipoic acid upon challenge with GTN in vivo
or in vitro, it has been suggested that GTN-triggered ROS production
causes irreversible inhibition of the enzyme via formation of the sul-
fonic acid (−SO3H) group [36].
ROS are highly toxic to various sites of the mitochondrial respira-
tory chain, and inhibition of Complex I seems to be the most likely
consequence of this toxicity. We have demonstrated that GTN-
tolerance is accompanied by a marked reduction in NADH oxidation,
which is indicative of a reduction in Complex I activity and is pre-
vented by mitochondrial antioxidants. Further experiments that we
have carried out to analyze isolated Complex I-dependent respiration
in permeabilized HUVEC have demonstrated that, in the presence of
succinate, a Complex II electron donor added in order to bypass Com-
plex I-dependent respiration, GTN-treated cells exhibit O2 consump-
tion rates similar to those of controls. This conﬁrms that continuous
exposure to GTN mainly affects Complex I, although we cannot dis-
card that a decrease in the respiration of GTN-treated cells could indi-
cate mitochondrial permeability transition pore (PTP) opening. In this
sense, it has been described that matrix pyridine nucleotide release
following a permeability transition leads to respiratory inhibition
with Complex I substrates, and PTP opening induces a speciﬁc confor-
mational change of Complex I that (i) dramatically increases H2O2
production so long as electrons are provided to Complex I, and (ii) in-
hibits the physiological pathway of electrons inside Complex I [37].
Importantly, we did not detect induction of apoptosis nor changes
in the viability of the cells after treatment with GTN which rules out
the presence of a major opening of PTP at least within the time
frame studied.
Once again, MQ and GEE blocked the effects of GTN, highlighting
ROS-mediated damage of Complex I as the likely cause of respiration
deﬁciency. In addition, it has been described that sustained treatment
with GTN increases ischemic damage, thereby inducing ALDH-2 inac-
tivation. This is highly relevant given that ALDH-2 activity is known to
be crucial for cardioprotection from ischemia [38].
5. Conclusion
The present study demonstrates that prolonged exposure to GTN
induces oxidative stress, and highlights the mitochondria as both its
source and its target. Our results lead us to propose that the activity
of mitochondrial Complex I is undermined following continuous in-
cubation with GTN, and that this Complex plays a key role in the ad-
equate regulation of ROS production during GTN biotransformation;
in other words, GTN metabolization depends on the ability of mito-
chondrial Complex I (NADH-ubiquinone oxidoreductase) to reoxidize
the NADH generated from NAD+ by ALDH-2 (see supplementary
Fig. 4). Our data provide fresh insight into the mechanisms responsi-
ble for nitrate tolerance and suggest that enhancing the activity of
ALDH-2 and Complex I is a potentially beneﬁcial strategy to adopt
in the case of patients with cardiac ischemia and those receiving
chronic treatment with GTN.
6. Abbreviations
ALDH-2 Aldehyde dehydrogenase 2
BPDS Bathophenanthroline disulfonic acid
CMFDA 5-Chloromethylﬂuorescein diacetate
DAF-FM Diaminodiﬂuoroﬂuorescein diacetate
DCFH-DA 2′,7′-Dichlorodihydroﬂuorescein diacetate
837R. Garcia-Bou et al. / Biochimica et Biophysica Acta 1817 (2012) 828–837DETA-NO1-[N-(2-Aminoethyl)-N-(2-ammonioethyl)amino]diazen-
1-ium-1,2-diolate
DTNB 5-5′-Dithiobis[2-nitrobenzoic acid
ETC Electron transport chain
FBS Fetal bovine serum
GEE Glutathione ester
GSH Glutathione
GSSG Oxidized glutathione
GTN Glyceryl trinitrate
H2O2 Hydrogen peroxide
HUAEC Human umbilical aortic endothelial cells
HUVEC Human umbilical vein endothelial cells
MQ Mitoquinone
NEM N-ethylmaleimide
NO Nitric oxide
ODQ 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
Phe Phenylephrine
ROS Reactive oxygen species
sGC Soluble guanylate cyclase
TPP Triphenylphosphonium
TPMP Methyltriphenylphosphonium
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbabio.2012.02.013.
Acknowledgements
We thank B. Normanly for his editorial assistance. We thank Dr. A.
Rotig (INSERM, Paris, France) for kindly donating Complex I mutant
cells and Dr. Stamler (Duke University, USA) for gently donated
ALDH-2 antibody. This study was ﬁnanced by grants PI10/1195,
PI09/01025, CIBERehd, PROMETEO 2010/060, ACOMP/2012/045 and
AP192/11. V.M.V. and M.R. are recipients of the Regional Ministry of
Health of Valencian Community and Carlos III Health Institute con-
tracts (CES10/030 and CP10/0360 respectively). N.A. is a recipient of
VALi+D contract (APOSTD/2011/049).
References
[1] J.D. Parker, J.O. Parker, Nitrate therapy for stable angina pectoris, N. Engl. J. Med.
338 (1998) 520–531.
[2] A. Mulsch, A. Bara, P. Mordvintcev, A. Vanin, R. Busse, Speciﬁcity of different or-
ganic nitrates to elicit NO formation in rabbit vascular tissues and organs
in vivo, Br. J. Pharmacol. 116 (1995) 2743–2749.
[3] T. Munzel, H. Sayegh, B.A. Freeman, M.M. Tarpey, D.G. Harrison, Evidence for en-
hanced vascular superoxide anion production in nitrate tolerance A novel mecha-
nism underlying tolerance and cross-tolerance, J. Clin. Invest. 95 (1995) 187–194.
[4] J.D. Artz, V. Toader, S.I. Zavorin, B.M. Bennet, G.R. Thatcher, In vitro activation of
soluble guanylyl cyclase and nitric oxide release: a comparison of NO donors
and NO mimetics, Biochemistry 40 (2001) 9256–9264.
[5] G.R. Thatcher, A.C. Nicolescu, B.M. Bennett, V. Toader, Nitrates and NO release:
contemporary aspects in biological and medicinal chemistry, Free Radic. Biol.
Med. 37 (2004) 1122–1143.
[6] Z. Chen, J. Zhang, J.S. Stamler, Identiﬁcation of the enzymatic mechanism of nitro-
glycerin bioactivation, Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 8306–8311.
[7] Z. Chen, M.W. Foster, J. Zhang, L. Mao, H.A. Rockman, T. Kawamoto, K. Kitagawa,
K.I. Nakayama, D.T. Hess, J.S. Stamler, An essential role for mitochondrial alde-
hyde dehydrogenase in nitroglycerin bioactivation, Proc. Natl. Acad. Sci. U. S. A.
102 (2005) 12159–12164.
[8] J.D. Artz, B. Schmidt, J.L. McCracken, M.A. Marletta, Effects of nitroglycerin on sol-
uble guanylate cyclase: implications for nitrate tolerance, J. Biol. Chem. 277
(2002) 18253–18256.
[9] K. Sydow, A. Daiber, M. Oelze, Z. Chen, M. August, M. Wendt, V. Ullrich, A. Mulsch,
E. Schulz, J.F. Jr Keaney, J.S. Stamler, T. Munzel, Central role of mitochondrial alde-
hyde deshidrogenase and reactive oxygen species in nitroglycerin tolerance and
cross-tolerance, J. Clin. Invest. 113 (2004) 482–489.
[10] A. Daiber, T. Munzel, Oxidative Stress, Redox Regulation and NO-bioavailability—
Experimental and Clinical Aspects, Steinkopff Verlag, Darmstadt, 2006 German.
[11] J.V. Esplugues, M. Rocha, C. Nuñez, I. Bosca, S. Ibiza, J.R. Herance, A. Ortega, J.M.
Serrador, P. D'Ocon, V.M. Victor, Complex I dysfunction and tolerance to nitro-
glycerin: an approach based on mitochondria-targeted antioxidants, Circ. Res.
99 (2006) 1067–1075.
[12] M.P. Murphy, R.A. Smith, Targeting antioxidants to mitochondria by conjugation
to lipophilic cations, Annu. Rev. Pharmacol. Toxicol. 47 (2007) 629–656.[13] M.P. Murphy, Targeting lipophilic cations to mitochondria, Biochim. Biophys. Acta
1777 (2008) 1028–1031.
[14] M.L. Jauslin, T. Meier, R.A. Smith, M.P. Murphy, Mitochondria-targeted antioxidants
protect Friedreich Ataxia ﬁbroblats from endogenous oxidative stress more effec-
tively than untargeted antioxidants, FASEB J. 17 (2003) 1972–1974.
[15] V.J. Adlam, J.C. Harrison, C.M. Porteous, A.M. James, R.A. Smith, M.P. Murphy, I.A.
Sammut, Targeting an antioxidant to mitochondria decreases cardiac ischemia–
reperfusion injury, FASEB J. 19 (2005) 1088–1095.
[16] J.S. Armstrong, Mitochondria-directed therapeutics, Antioxid. Redox Signal. 10
(2008) 575–578.
[17] A.L. Ortega, J. Carretero, E. Obrador, J. Gambini, M. Asensi, V. Rodilla, J.M. Estrela,
Tumor toxicity by endothelial cells. Impairment of the mitochondrial system for
glutathione uptake in mouse B16 melanoma cells that survive after in vitro inter-
action with the hepatic sinusoidal endothelium, J. Biol. Chem. 278 (2003)
13888–13897.
[18] E. Dejana, S. Colella, L.R. Languino, G. Balconi, G.C. Corbascio, P.C. Marchisio, Fi-
brinogen induces adhesion, spreading, and microﬁlament organization of
human endothelial cells in vitro, J. Cell Biol. 104 (1987) 1403–1411.
[19] C. Nuñez, V.M. Victor, R. Tur, A. Alvarez-Barrientos, S. Moncada, J.V. Esplugues, P.
D'Ocon, Discrepancies between nitroglycerin and NO-releasing drugs on mito-
chondrial oxygen consumption, vasoactivity, and the release of NO, Circ. Res. 97
(2005) 1063–1069.
[20] S. Ibiza, V.M. Victor, I. Bosca, A. Ortega, A. Urzainqui, J.E. O'Connor, F. Sanchez-
Madrid, J.V. Esplugues, J.M. Serrador, Endothelial nitric oxide synthase regulates T
cell receptor signaling at the immunological synapse, Immunity 24 (2006) 753–765.
[21] A. Hernandez-Mijares, M. Rocha, N. Apostolova, C. Borras, A. Jover, C. Bañuls, E.
Sola, V.M. Victor, Mitochondrial Complex I impairment in leukocytes from type
2 diabetic patients, Free Radic. Biol. Med. 50 (2011) 1215–1221.
[22] A. Sanjuan-Pla, A.M. Cervera, N. Apostolova, R. Garcia-Bou, V.M. Victor, M.P.
Murphy, K.J. McCreath, A targeted antioxidant reveals the importance of mito-
chondrial reactive oxygen species in the hypoxic signaling of HIF-1 alpha, FEBS
Lett. 579 (2005) 2669–2674.
[23] M. Asensi, J. Sastre, F.V. Pallardo, J.M. Estrela, J. Viña, Determination of oxidized
glutathione in blood: high-performance liquid chromatography, Methods Enzy-
mol. 234 (1994) 367–371.
[24] C.I. Ragan, M.T. Wilson, V.M. Darley-Usmar, P.N. Lowe, in: V.M. Darley-Usmar, D.
Rickwood, M.T. Wilson (Eds.), Mitochondria: A Practical Approach, IRL, Oxford,
UK, 1997, pp. 79–112.
[25] N. Apostolova, A.M. Cervera, V.M. Victor, S. Cadenas, A. Sanjuan-Pla, A.
Alvarez-Barrientos, J.V. Esplugues, K.J. McCreath, Loss of apoptosis-inducing
factor leads to an increase in reactive oxygen species, and an impairment of
respiration that can be reversed by antioxidants, Cell Death Differ. 13
(2006) 354–357.
[26] G.F. Kelso, C.M. Porteous, C.V. Coulter, G. Hughes, W.K. Porteous, E.C. Ledgerwood,
R.A. Smith, M.P. Murphy, Selective targeting of a redox-active ubiquinone to mi-
tochondria within cells: antioxidant and antiapoptotic properties, J. Biol. Chem.
276 (2001) 4588–4596.
[27] N. Apostolova, R. Garcia-Bou, A. Hernandez-Mijares, R. Herance, M. Rocha, V.M.
Victor, Mitochondrial antioxidants alleviate oxidative and nitrosative stress in a
cellular model of sepsis, Pharm. Res. 28 (2011) 2910–2919.
[28] I.S. Hanspal, K.S. Magid, D.J. Webb, I.L. Megson, The effect of oxidative stress on
endothelium-dependent and nitric oxide donor-induced relaxation: implications
for nitrate tolerance, Nitric Oxide 6 (2002) 263–270.
[29] A. Daiber, A. Mulsch, U. Hink, H. Mollnau, A. Warnholtz, M. Oelze, T. Munzel, The
oxidative stress concept of nitrate tolerance and the antioxidant properties of hy-
dralazine, Am. J. Cardiol. 96 (2005) 25–36.
[30] A. Mulsch, M. Oelze, S. Kloss, H. Mollnau, A. Topfer, A. Smolenski, U. Walter, J.P.
Stasch, A. Warnholtz, U. Hink, T. Meinertz, T. Munzel, Effects of in vivo nitroglyc-
erin treatment on activity and expression of the guanylyl cyclase and cGMP-
dependent protein kinase and their downstream target vasodilator-stimulated
phosphoprotein in aorta, Circulation 103 (2001) 2188–2194.
[31] T. Munzel, A. Daiber, A. Mulsch, Explaining the phenomenon of nitrate tolerance,
Circ. Res. 97 (2005) 618–628.
[32] J.D. Parker, Nitrate tolerance, oxidative stress, and mitochondrial function:
another worrisome chapter on the effects of organic nitrates, J. Clin. Invest. 113
(2004) 352–354.
[33] A. Daiber, M. Oelze, M. Coldewey, M. Bachschmid, P. Wenzel, K. Sydow, M.
Wendt, A.L. Kleschyov, D. Stalleicken, V. Ullrich, A. Mülsch, T. Münzel, Oxidative
stress and mitochondrial aldehyde dehydrogenase activity: a comparison of
pentaerythritol tetranitrate with other organic nitrates, Mol. Pharmacol. 66
(2004) 1372–1382.
[34] H.L. Fung, Biochemical mechanism of nitroglycerin action and tolerance: is this
old mystery solved? Annu. Rev. Pharmacol. Toxicol. 44 (2004) 67–85.
[35] A. Daiber, P. Wenzel, M. Oelze, T. Munzel, New insights into bioactivation of or-
ganic nitrates, nitrate tolerance and cross-tolerance, Clin. Res. Cardiol. 97
(2008) 12–20.
[36] A. Daiber, M. Oelze, P. Wenzel, J.M. Wickramanayake, S. Schuhmacher, T. Jansen,
K.J. Lackner, M. Torzewski, T. Münzel, Nitrate tolerance as a model of vascular
dysfunction: roles for mitochondrial aldehyde dedydrogenase and mitochondrial
oxidative stress, Pharmacol. Rep. 61 (2009) 33–48.
[37] C. Batandier, X. Leverve, E. Fontaine, Opening of the mitochondrial permeability
transition pore induces reactive oxygen species production at the level of the re-
spiratory chain Complex I, J. Biol. Chem. 279 (2004) 17197–17204.
[38] C.H. Chen, G. Budas, E.N. Churchill, M.H. Disatnik, T.D. Hurley, D.M. Rosen, Activa-
tion of aldehyde dehydrogenase-2 reduces ischemic damage to the heart, Science
321 (2008) 1493–1495.
